23-valent pneumococcal polysaccharide vaccine

MSD's Capvaxive, a groundbreaking 21-valent pneumococcal vaccine, receives FDA approval as the first shot specifically designed for adults, covering 84% of invasive pneumococcal disease cases in those over 50.

The European Medicines Agency's CHMP recommended CAPVAXIVE for active immunization against invasive pneumococcal disease and pneumonia in adults 18 and older.

Sanofi and SK bioscience have initiated global Phase III trials for their 21-valent pneumococcal conjugate vaccine candidate, GBP410, targeting individuals aged six weeks to 17 years.

Merck's CAPVAXIVE, a 21-valent pneumococcal conjugate vaccine, has demonstrated robust immune responses in adults, particularly those with increased risk factors for pneumococcal disease.

AIM Vaccine's iterative serum-free rabies vaccine demonstrated strong immunogenicity and safety in Phase III trials, meeting all pre-set clinical objectives.